211 related articles for article (PubMed ID: 29998767)
21. [Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution)].
Ge J; Li X; Sun X; He X; Zhang H
Zhonghua Yan Ke Za Zhi; 2015 Feb; 51(2):95-102. PubMed ID: 25907999
[TBL] [Abstract][Full Text] [Related]
22. Comparison of ocular surface assessment and adherence between preserved and preservative-free latanoprost in glaucoma: a parallel-grouped randomized trial.
Kim DW; Shin J; Lee CK; Kim M; Lee S; Rho S
Sci Rep; 2021 Jul; 11(1):14971. PubMed ID: 34294842
[TBL] [Abstract][Full Text] [Related]
23. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost.
Gandolfi SA; Cimino L
Ophthalmology; 2003 Mar; 110(3):609-14. PubMed ID: 12623831
[TBL] [Abstract][Full Text] [Related]
24. [Ocular Surface Evaluation in Patients Treated with Prostaglandin Analogues Considering Preservative Agent].
Mlčáková E; Mlčák P; Karhanová M; Langová K; Marešová K
Cesk Slov Oftalmol; 2016; 72(4):120-127. PubMed ID: 27860477
[TBL] [Abstract][Full Text] [Related]
25. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension.
Konstas AG; Quaranta L; Katsanos A; Riva I; Tsai JC; Giannopoulos T; Voudouragkaki IC; Paschalinou E; Floriani I; Haidich AB
Br J Ophthalmol; 2013 Dec; 97(12):1510-5. PubMed ID: 23681371
[TBL] [Abstract][Full Text] [Related]
26. Ocular Surface Disease in Glaucoma Patients Randomized to Benzalkonium Chloride-Containing Latanoprost and Preservative-Free Bimatoprost.
Wu JH; Wang TH; Huang JY; Su CC
J Ocul Pharmacol Ther; 2021 Dec; 37(10):556-564. PubMed ID: 34610257
[No Abstract] [Full Text] [Related]
27. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study.
Uusitalo H; Pillunat LE; Ropo A;
Acta Ophthalmol; 2010 Feb; 88(1):12-9. PubMed ID: 20420586
[TBL] [Abstract][Full Text] [Related]
28. Switch from BAK-preserved to preservative-free latanoprost decreases anterior chamber flare in POAG patients.
Kestelyn PA; Kestelyn PG; De Bacquer D; Stevens AM
Int Ophthalmol; 2019 Jan; 39(1):105-109. PubMed ID: 29274019
[TBL] [Abstract][Full Text] [Related]
29. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension.
Lin L; Zhao YJ; Chew PT; Sng CC; Wong HT; Yip LW; Wu TS; Bautista D; Teng M; Khoo AL; Lim BP
Ann Pharmacother; 2014 Dec; 48(12):1585-93. PubMed ID: 25184309
[TBL] [Abstract][Full Text] [Related]
30. Long term safety and tolerability of Tafluprost 0.0015% vs Timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: a cross sectional study.
Rolle T; Spinetta R; Nuzzi R
BMC Ophthalmol; 2017 Aug; 17(1):136. PubMed ID: 28768500
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of locally produced Latanoprost in the control of intraocular pressure in patients with primary open-angle glaucoma.
Mahar PS; Butt NH; Ali SI
Int Ophthalmol; 2018 Dec; 38(6):2593-2597. PubMed ID: 29209880
[TBL] [Abstract][Full Text] [Related]
32. Tolerability and efficacy of bimatoprost 0.01 % in patients with open-angle glaucoma or ocular hypertension evaluated in the Taiwanese clinical setting: the Asia Pacific Patterns from Early Access of Lumigan 0.01 % (APPEAL Taiwan) study.
Chen YY; Wang TH; Liu C; Wu KY; Chiu SL; Simonyi S; Lu DW
BMC Ophthalmol; 2016 Sep; 16(1):162. PubMed ID: 27633513
[TBL] [Abstract][Full Text] [Related]
33. 24-hour efficacy of travoprost/timolol BAK-free versus latanoprost/timolol fixed combinations in patients insufficiently controlled with latanoprost.
Konstas AG; Voudouragkaki IC; Boboridis KG; Haidich AB; Paschalinou E; Giannopoulos T; Dragoumis ND; Makridis AK; Kahook MY
Adv Ther; 2014 Jun; 31(6):592-603. PubMed ID: 24919410
[TBL] [Abstract][Full Text] [Related]
34. Crossover randomized study comparing the efficacy and tolerability of preservative-free Tafluprost 0.0015% to Latanoprost 0.005% in patients with primary open-angle glaucoma.
Hagras SM; Al-Duwailah OKH; Nassief MA; Abdelhameed AG
Indian J Ophthalmol; 2021 Sep; 69(9):2475-2480. PubMed ID: 34427247
[TBL] [Abstract][Full Text] [Related]
35. Effects of SofZia-preserved travoprost and benzalkonium chloride-preserved latanoprost on the ocular surface -- a multicentre randomized single-masked study.
Aihara M; Oshima H; Araie M;
Acta Ophthalmol; 2013 Feb; 91(1):e7-e14. PubMed ID: 23241328
[TBL] [Abstract][Full Text] [Related]
36. A randomized, 36-month, post-marketing efficacy and tolerability study in Sweden and Finland of latanoprost versus non-prostaglandin therapy in patients with glaucoma or ocular hypertension.
Friström B; Uusitalo H
Acta Ophthalmol; 2010 Feb; 88(1):37-43. PubMed ID: 19900212
[TBL] [Abstract][Full Text] [Related]
37. Use of a Cationic Emulsion of Latanoprost to Treat Glaucoma Patients with Ocular Surface Disease: A Preclinical Review.
Daull P; Garrigue JS; Liang H; Baudouin C
J Ocul Pharmacol Ther; 2023 May; 39(4):240-251. PubMed ID: 37015075
[TBL] [Abstract][Full Text] [Related]
38. Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma.
Gandolfi S; Paredes T; Goldberg I; Coote M; Wells A; Volksone L; Pillai MR; Stalmans I; Denis P;
Eur J Ophthalmol; 2012; 22(1):34-44. PubMed ID: 22167541
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and tolerability of preservative-free eye drops containing a fixed combination of dorzolamide and timolol in glaucoma patients.
Renieri G; Führer K; Scheithe K; Lorenz K; Pfeiffer N; Thieme H
J Ocul Pharmacol Ther; 2010 Dec; 26(6):597-603. PubMed ID: 20977366
[TBL] [Abstract][Full Text] [Related]
40. A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension.
Schachar RA; Raber S; Courtney R; Zhang M
Curr Eye Res; 2011 Sep; 36(9):809-17. PubMed ID: 21851167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
